SUPPRELIN LA
Post-LOEhistrelin acetate
NDASUBCUTANEOUSIMPLANT
Approved
May 2007
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUPPRELIN LA is a subcutaneous implant containing histrelin acetate, a gonadotropin-releasing hormone (GnRH) agonist approved in 2007. It is indicated for central precocious puberty (CPP) in children, where it suppresses the early activation of the hypothalamic-pituitary-gonadal axis. The implant delivers continuous hormone suppression over 12 months, offering a long-acting alternative to injectable formulations.
Post-LOEPost-LOE
Product is in post-LOE phase with moderate competitive pressure (35%), suggesting a stable but mature commercial footprint requiring specialized expertise rather than growth-oriented hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.